Indisulam Shows an Anti-Cancer Effect on HPV+ and HPV− Head and Neck Cancer
Cancers · 22.03.2025 · 17 (7) · 1072
DOI: 10.3390/cancers17071072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 22.03.2025. Verfasst von Tara M Hosseini und 3 weiteren Autor:innen. Beteiligte Einrichtung: Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, University of California San Diego Altman Clinical and Translational Research Institute.
Abstract (Originalsprache)
Background/Objectives: HPV+ head and neck squamous cell carcinoma has been shown to have a unique genomic background, requiring researchers to study it as its own distinct type of cancer. HPV+ tumors have been shown to exhibit fewer genetic mutations in cancer drivers as opposed to their HPV− counterparts. In this paper, we explored how targeting post-transcriptional changes, specifically alternative splicing events, could serve as a potential mechanism to treat HPV+ cancer.
Methods
Using indisulam, a drug that targets alternative splicing through the degradation of RBM39, we treated various HPV+ and HPV− cell lines and assessed tumor cell viability. We also tested indisulam in vivo to evaluate its effect on tumor volume. Additionally, we analyzed gene expression differences between indisulam-treated subjects and their non-treated counterparts.
Results
Indisulam treatment led to a reduction in tumor cell viability in both HPV+ and HPV− cell lines. In vivo experiments showed a reduction in tumor volume following indisulam treatment. Gene expression analysis revealed that indisulam induces consistent differential gene expression changes and highly enriches interferon pathways in treated HPV+ cell lines.
Conclusions
These findings suggest that targeting alternative splicing via indisulam may be a promising therapeutic approach for HPV+ cancers. Further research is required to establish indisulam as a viable anti-cancer treatment in clinical settings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
- Department of Otolaryngology-Head & Neck Surgery, University of California San Diego, La Jolla, CA 92093, USA.
ORCID-Profile: Joseph Bendik, Theresa Guo
Förderung
- NCI NIH HHS
- NCATS NIH HHS
- University of California San Diego Altman Clinical and Translational Research Institute
- National Cancer Institute
Zitieren
APA
Hosseini, T. M., Jang, S. S., Bendik, J., & Guo, T. (2025). Indisulam Shows an Anti-Cancer Effect on HPV+ and HPV− Head and Neck Cancer. Cancers, 17(7), 1072. https://doi.org/10.3390/cancers17071072
Vancouver
Hosseini TM, Jang SS, Bendik J, Guo T. Indisulam Shows an Anti-Cancer Effect on HPV+ and HPV− Head and Neck Cancer. Cancers. 2025;17(7):1072. doi:10.3390/cancers17071072
BibTeX
@article{Hosseini2025,
author = {Hosseini, Tara M and Jang, Sophie S and Bendik, Joseph and Guo, Theresa},
title = {Indisulam Shows an Anti-Cancer Effect on HPV+ and HPV− Head and Neck Cancer},
journal = {Cancers},
year = {2025},
volume = {17},
number = {7},
pages = {1072},
doi = {10.3390/cancers17071072}
}
EUVIMED